Neuropace (NPCE) vs Tactile Systems Technology (TCMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tactile Systems Technology (TCMD) has outperformed Neuropace (NPCE) over the past year, gaining 48.4% versus a gain of 19.8%. Over five years, NPCE leads with a -18.6% price change compared with -38.0% for TCMD. Tactile Systems Technology is the larger company by market cap ($498.8 million vs $438.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NPCE | TCMD |
|---|---|---|
| Share price | $12.76 | $22.02 |
| Market cap | $437.98M | $498.80M |
| 1-day change | +0.71% | -0.77% |
| YTD return | -17.36% | -24.07% |
| 1-year return | +19.81% | +48.38% |
| 5-year return | -18.57% | -37.97% |
| P/E ratio (TTM) | — | 20.39 |
| Forward P/E | — | 15.13 |
| EPS (TTM) | $-0.57 | $1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.60 | $37.77 |
| 52-week low | $9.22 | $14.00 |
| Distance from 52-week high | -34.90% | -41.70% |
| Analyst consensus | none | none |
| Avg. price target upside | +56.74% | +77.11% |
| Average volume | 170.54K | 294.17K |
| Shares outstanding | 34.32M | 22.65M |
| Employees | 220 | 1,086 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TCMD has outperformed NPCE by 28.6 percentage points over the past year.
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Healthcare · Medical Devices · 220 employees
About Tactile Systems Technology
TCMD stock →Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Healthcare · Medical Devices · 1,086 employees
NPCE vs TCMD FAQ
Which is bigger, Neuropace or Tactile Systems Technology?
Tactile Systems Technology (TCMD) is larger, with a market capitalization of $498.80M compared with $437.98M for Neuropace (NPCE).
Which stock has performed better over the past year, NPCE or TCMD?
TCMD returned +48.38% over the past 12 months, compared with +19.81% for NPCE (price return, excluding dividends). Past performance does not predict future results.
Are Neuropace and Tactile Systems Technology in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.